Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP,Strategy/Corp Development | May 27, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 27, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 98,611 |
Reported balance
After 2026-05-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-27 · Sale · Disposed 23,145 · Balance 98,611 F1: This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Direct | 22,798.2532 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 22,798.2532 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 30,969.5756 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 30,969.5756 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $86.27 to $86.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 08, 2021 Filed Jan 9, 2021 00:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,400 | $90.22 | $757,848.84 |
DisclosureSEC source: 0001225208-21-000703 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,507.8812 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $89.6500 to $90.6400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2021 Filed Jan 9, 2021 00:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,677 | $90.85 | $424,907.32 |
DisclosureSEC source: 0001225208-21-000703 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,907.8812 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $90.7100 to $91.2000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2021 Filed Jan 9, 2021 00:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,077 | $13.98 | $182,816.46 |
DisclosureSEC source: 0001225208-21-000703 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,584.8812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. Read SEC document |
| December 11, 2020 Filed Dec 11, 2020 22:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,074 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-20-014620 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,308 Underlying: Common Stock · 13,074 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2020 Filed Dec 11, 2020 22:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 12,774 | $84.63 | $1,081,021.47 |
DisclosureSEC source: 0001225208-20-014620 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,507.8812 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $84.4200 to $85.4100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 11, 2020 Filed Dec 11, 2020 22:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 300 | $85.59 | $25,677.99 |
DisclosureSEC source: 0001225208-20-014620 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,281.8812 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $85.5000 to $85.6400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 11, 2020 Filed Dec 11, 2020 22:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,074 | $13.98 | $182,774.52 |
DisclosureSEC source: 0001225208-20-014620 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,581.8812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. Read SEC document |
| November 13, 2020 Filed Nov 13, 2020 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,074 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-20-013538 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,382 Underlying: Common Stock · 13,074 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2020 Filed Nov 13, 2020 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 12,213 | $80.52 | $983,440.83 |
DisclosureSEC source: 0001225208-20-013538 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,507.8812 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $80.0400 to $81.0300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 13, 2020 Filed Nov 13, 2020 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 861 | $81.09 | $69,819.44 |
DisclosureSEC source: 0001225208-20-013538 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,720.8812 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $81.0500 to $81.1700. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 13, 2020 Filed Nov 13, 2020 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,074 | $13.98 | $182,774.52 |
DisclosureSEC source: 0001225208-20-013538 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,581.8812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 01:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 226.8579 | $83.89 | $19,029.97 |
DisclosureSEC source: 0001225208-20-013270 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Son Disclosed balance after: 403.1421 F1 · balance_after: The amount of securities beneficially owned includes 449 shares of the Issuer's common stock, including 226.8579 shares reported as sold in this Form 4, that were inadvertently omitted from previous Form 4 filings after being acquired by the Reporting Person's son pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 01:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 347 | $78.01 | $27,068.74 |
DisclosureSEC source: 0001225208-20-013270 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Son Disclosed balance after: 630 F1 · balance_after: The amount of securities beneficially owned includes 449 shares of the Issuer's common stock, including 226.8579 shares reported as sold in this Form 4, that were inadvertently omitted from previous Form 4 filings after being acquired by the Reporting Person's son pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 09, 2020 Filed Oct 9, 2020 23:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,074 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-20-012406 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,456 Underlying: Common Stock · 13,074 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. Read SEC document |
| October 09, 2020 Filed Oct 9, 2020 23:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 13,074 | $82.61 | $1,079,997.38 |
DisclosureSEC source: 0001225208-20-012406 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,507.8812 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $82.00 to $82.92. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 09, 2020 Filed Oct 9, 2020 23:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,074 | $13.98 | $182,774.52 |
DisclosureSEC source: 0001225208-20-012406 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,581.8812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. Read SEC document |
| September 11, 2020 Filed Sep 11, 2020 21:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,074 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-20-011445 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,530 Underlying: Common Stock · 13,074 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. Read SEC document |
| September 11, 2020 Filed Sep 11, 2020 21:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 12,198 | $82.42 | $1,005,364.04 |
DisclosureSEC source: 0001225208-20-011445 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,507.8812 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $81.83 to $82.82 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 11, 2020 Filed Sep 11, 2020 21:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 876 | $82.90 | $72,623.99 |
DisclosureSEC source: 0001225208-20-011445 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,705.8812 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $82.83 to $82.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 11, 2020 Filed Sep 11, 2020 21:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,074 | $13.98 | $182,774.52 |
DisclosureSEC source: 0001225208-20-011445 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,581.8812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 20:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,200 | $84.26 | $606,693.60 |
DisclosureSEC source: 0001225208-20-011098 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 123,820 F1 · price: This transaction was executed in multiple trades at prices ranging from $83.950 to $84.530. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 14, 2020 Filed Aug 14, 2020 22:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,074 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-20-010667 · doc4.xml · derivative · entry 8 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,604 Underlying: Common Stock · 13,074 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. Read SEC document |
| August 14, 2020 Filed Aug 14, 2020 22:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 13,074 | $78.75 | $1,029,604.96 |
DisclosureSEC source: 0001225208-20-010667 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,507.8812 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $78.5900 to $79.0000. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 14, 2020 Filed Aug 14, 2020 22:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,074 | $13.98 | $182,774.52 |
DisclosureSEC source: 0001225208-20-010667 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,581.8812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 22:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-010667 · doc4.xml · nonDerivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 131,020 Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 22:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 24,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-010667 · doc4.xml · nonDerivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 136,020 F1 · shares: On August 13, 2020, the Insider transfered 24,324 common shares into his trust. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 22:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 24,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-010667 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,507.8812 F1 · shares: On August 13, 2020, the Insider transfered 24,324 common shares into his trust. Read SEC document |
| August 06, 2020 Filed Aug 8, 2020 00:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 12,000 | $77.28 | $927,378.00 |
DisclosureSEC source: 0001225208-20-010434 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 111,696 F1 · price: This transaction was executed in multiple trades at prices ranging from $77.12 to $77.445. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 10, 2020 Filed Jul 10, 2020 21:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,074 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-20-009712 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,678 Underlying: Common Stock · 13,074 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. Read SEC document |
| July 10, 2020 Filed Jul 10, 2020 21:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 10,849 | $67.31 | $730,291.76 |
DisclosureSEC source: 0001225208-20-009712 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,831.8812 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $66.91 to $67.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 10, 2020 Filed Jul 10, 2020 21:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,225 | $68.20 | $151,740.11 |
DisclosureSEC source: 0001225208-20-009712 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,680.8812 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $67.96 to $68.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 10, 2020 Filed Jul 10, 2020 21:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,074 | $13.98 | $182,774.52 |
DisclosureSEC source: 0001225208-20-009712 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,905.8812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. Read SEC document |
| June 12, 2020 Filed Jun 12, 2020 21:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,074 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-20-008937 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,752 Underlying: Common Stock · 13,074 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. Read SEC document |
| June 12, 2020 Filed Jun 12, 2020 21:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 13,074 | $69.86 | $913,313.03 |
DisclosureSEC source: 0001225208-20-008937 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,751.5507 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $69.51 to $70.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 12, 2020 Filed Jun 12, 2020 21:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 13,074 | $13.98 | $182,774.52 |
DisclosureSEC source: 0001225208-20-008937 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,825.5507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. Read SEC document |
| May 15, 2020 Filed May 15, 2020 20:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,358 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-20-007835 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,942 Underlying: Common Stock · 4,358 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. Read SEC document |
| May 15, 2020 Filed May 15, 2020 20:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,358 | $215.16 | $937,667.28 |
DisclosureSEC source: 0001225208-20-007835 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,250.5169 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. Read SEC document |
| May 15, 2020 Filed May 15, 2020 20:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,358 | $41.94 | $182,774.52 |
DisclosureSEC source: 0001225208-20-007835 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,608.5169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2020. Read SEC document |
| May 12, 2020 Filed May 13, 2020 20:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 709 | $225.05 | $159,560.45 |
DisclosureSEC source: 0001225208-20-007572 · doc4.xml · nonDerivative · entry 4 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,250.5169 Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 6,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007572 · doc4.xml · derivative · entry 8 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,343 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · derivative.exercise_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · derivative.expiration_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · derivative.underlying_shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 3,145 | $217.84 | $685,106.80 |
DisclosureSEC source: 0001225208-20-007572 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,959.5169 Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 685 | $217.84 | $149,220.40 |
DisclosureSEC source: 0001225208-20-007572 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,104.5169 Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007572 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,789.5169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. Read SEC document |
| May 08, 2020 Filed May 8, 2020 23:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,372 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-20-007337 · doc4.xml · derivative · entry 9 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,372 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| May 08, 2020 Filed May 8, 2020 23:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,372 | $220.94 | $1,186,889.68 |
DisclosureSEC source: 0001225208-20-007337 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,446.5169 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| May 08, 2020 Filed May 8, 2020 23:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,372 | $35.79 | $192,237.02 |
DisclosureSEC source: 0001225208-20-007337 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,818.5169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 2,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007337 · doc4.xml · derivative · entry 8 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,025 Underlying: Common Stock · 2,025 shares Expires 2027-05-06 F5 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F5 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F5 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F5 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F5 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 16,300 | $0.00 Strike: $218.04 | $0.00 |
DisclosureSEC source: 0001225208-20-007337 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 Underlying: Common Stock · 16,300 shares Expires 2027-05-06 F4 · derivative.exercise_date: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007337 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,446.5169 F1 · shares: These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| April 03, 2020 Filed Apr 3, 2020 22:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,369 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-20-006081 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,372 Underlying: Common Stock · 5,369 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.